From the Guidelines

Subdural hematoma is a potential risk associated with the use of Brilinta (ticagrelor), a antiplatelet agent.

The evidence suggests that patients with acute intracranial bleeding, including subdural hematoma, on oral anticoagulants or antiplatelet agents, such as Brilinta, have a poor prognosis 1.
The management of antithrombotic therapy in patients who suffer an intracranial hemorrhage, including subdural hematoma, is challenging, and the risk of recurrent hemorrhage must be weighed against the risk of an ischemic cerebrovascular event 1.
In patients with a nonmajor bleed, including subdural hematoma, on Brilinta, temporary discontinuation of the medication may be considered until the patient is clinically stable and hemostasis has been achieved 1.
The use of Brilinta, a reversible platelet inhibitor with a half-life of 7 to 9 hours, may be associated with a higher risk of bleeding, including subdural hematoma, compared to other antiplatelet agents 1.
The decision to restart antithrombotic therapy, including Brilinta, after an intracranial hemorrhage, including subdural hematoma, should be made on a case-by-case basis, taking into account the individual patient's risk factors and the indication for antithrombotic therapy 1.

From the Research

The use of antiplatelet agents, such as Brilinta (ticagrelor), has been associated with an increased risk of subdural hematoma, particularly in the elderly population 2, 3.
A study published in 2015 reported a case of spontaneous acute subdural hematoma in a patient on antiplatelet therapy with aspirin and ticagrelor, highlighting the potential risk of intracranial hemorrhage with these medications 3.
Another study from 2016 found that the use of anticoagulants and antiplatelet agents in elderly patients with acute subdural hematomas was associated with larger hematomas and poor outcomes 2.
However, it is worth noting that the management of subdural hematomas in patients on antiplatelet therapy, such as ticagrelor, may involve reversal of anticoagulation and antiplatelet medications, as well as close monitoring and medical management 4, 5.
The overall relationship between subdural hematoma and Brilinta (ticagrelor) suggests that patients on this medication may be at increased risk of developing subdural hematomas, particularly if they experience trauma or have underlying brain injury 2, 3.

Patients with subdural hematomas who are on ticagrelor may require reversal of anticoagulation and antiplatelet medications, as well as close monitoring and medical management 4, 5.
The management of subdural hematomas in these patients may involve a multidisciplinary approach, including neurosurgery, neurology, and critical care medicine 4, 6.
Early recognition and discontinuation of ticagrelor, as well as appropriate management, may result in resolution of the hematoma and good clinical outcome 3.